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Summary
  Background:  The subject of the study was determination of the effect of drugs on ileal smooth muscle con-
traction induced by activation of M1 type muscarinic receptors. Drugs that have an effect on mu-
scarinic receptors are divided to agonists, with close ties to the receptor and high internal activi-
ty and antagonists, with no internal activity. Conducted experiments tested interactions between 
a broad-spectrum agonist of muscarinic receptors, carbachol and a selective muscarinic receptor 
antagonist of M1 type, pirenzepine.
  Material/Methods:  Testing was conducted on tissues isolated from rat’s intestine. Male Wistar rats with weight be-
tween 220 g and 360 g were anesthetized by intraperitoneal injection of urethane (120 mg/kg). 
Concentration-effect curves were determined with the use of cumulated concentration method, 
in accordance with the van Rossum method (1963) in Kenakin modification (2006).
  Results:  The purpose of the study was determination of concentration-effect curves for carbachol. This 
curve was compared with the curve of receptor occupation depending on concentration of this 
drug. Based on concentration-effect curves, the average value of EC50 was calculated for carba-
chol, amounting to 2.44×10–6 [M/l].
  Conclusions:  The results confirmed that atropine is effective in stopping contractions caused by carbachol, 
meeting the conditions of competitive antagonists. Atropine caused the shift of curves for carba-
chol to the right. Pirenzepine, selectively blocking muscarinic receptors of M1 type gave similar 
results. It was proved that in the preparation of gastric fundus smooth muscle, M1 type receptors 
occur not only presynaptically, but also postsynaptically.
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Streszczenie
  Wstęp:  Przedmiotem pracy jest określenie wpływu leków na skurcz mięśniówki gładkiej jelita krętego 
wyzwalany aktywacją receptorów muskarynowych typu M1. Leki wpływające na receptory mu-
skarynowe dzielą się na agonistów, leki o dużym powinowactwie do receptora i dużej aktywno-
ści wewnętrznej oraz antagonistów, niemających aktywności wewnętrznej. W przeprowadzonych 
doświadczeniach badano interakcje między szerokospektralnym agonistą receptorów muskaryno-
wych – karbacholem a selektywnym antagonistą receptorów muskarynowych M:1 – pirenzepiną.
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The subject of the study was determination of the ef-
fect of drugs on ileal smooth muscle contraction indu-
ced by activation of M1 type muscarinic receptors. Drugs 
that have an effect on muscarinic receptors are divided 
to agonists, with close ties to the receptor and high in-
ternal activity and antagonists, with no internal activi-
ty [1,4]. Conducted experiments tested interactions be-
tween a broad-spectrum agonist of muscarinic receptors, 
carbachol and a selective muscarinic receptor antagonist 
of M1 type, pirenzepine.
In accordance with the receptor theory, the condition for 
activity of drug is its reaction with the cell protein (recep-
tor), resulting in changes in its activity. Receptor means 
unique places of bonding of drug with the cell, which in-
termediate in activity of the drug. They can be found on 
the surface of the cell or inside cytoplasm [9]. Muscarinic 
receptors M1 are frequently called neuronal receptors. They 
occur on parietal cells, in the central and peripheral nervo-
us system. M1 receptors release stimulation effects; one of 
the examples is slow muscarinic stimulation depending on 
acetylcholine in sympathetic ganglions and central neurons 
[9,11,12]. This simulation is caused by drop in conduction 
for potassium ions, resulting in depolarization of the neu-
ronal membrane. Muscarinic receptors M1 also stimulate 
secretion of hydrochloric acid in the stomach after vagus 
nerve stimulation [2,9,15].
MaterIal and Methods
Testing was conducted on tissues isolated from rat’s in-
testine. Male Wistar rats with weight between 220 g and 
360 g were anesthetized by intraperitoneal injection of 
urethane (120 mg/kg). The intestine was dissected under 
anesthetic; after dissection it was cut out and placed in a 
dish for insulated organs with 20 ml in capacity, filled with 
oxidized Krebs fluid. Content of Krebs fluid: 71.8 mM 
NaCl, 4.7 mM KCl, 1.7 mM CaCl2, 28.4 mM NaHCO3, 
11.7 mM glucose, 2.4 mM MgSO4, 1.2 mM KH 2PO4. A 
series of testing with inadequate blood supply was con-
ducted under controlled conditions. The intestine was dis-
sected and arteries were pressed with Klem clamps for a 
period of 30 minutes, in order to induce ischemia; after 
that, Klem clamps were removed and the intestine was 
dissected after 90 minutes.
In addition to that testing, another one was performed; 
after 30 minutes from closing blood vessels vascularizing 
the intestine, Klem tools were used to dissect the organ. 
After that, it was placed in oxidized Krebs fluid, followed 
by analysis of reaction. Testing was carried out 30 minu-
tes after closing dishes and 90 minutes after reperfusion of 
the dish. Preparations were added to the dish in the amo-
unt between 0.1 ml and 0.3 ml.
Concentration-effect curves for tested agonists and anta-
gonists were determined with the use of the Van Rosum 
method – concentrations increasing every 0.5 log. Based 
on these concentration-effect curves, constants were de-
termined for tested agonists, specifying activity of a given 
preparation, i.e. EC50. The control curve of EC50 value was 
determined based on 25 curves and under controlled con-
ditions it amounts to 2.44(±0.11) ×10–7; it can serve as ba-
sis for recreation of the theoretical curve.
Concentration-effect curves were determined with the use 
of cumulated concentration method, in accordance with the 
van Rossum method (1963) in Kenakin modification (2006).
 Materiał/Metody:  Badania przeprowadzono na tkankach wyizolowanych z jelita szczura. Samce szczurów szcze-
pu Wistar o masie 220–360 g usypiano uretanem (120 mg/kgm.c.) wstrzykiwanym dootrzewno-
wo. Krzywe stężenie – efekt wyznaczano metodą stężeń kumulowanych, zgodnie z metodą van 
Rossuma (1963) w modyfikacji Kenakin (2006).
  Wyniki:  Celem pracy było wyznaczenie krzywych stężenie – efekt dla karbacholu. Krzywa ta została po-
równana z krzywą zajęcia receptorów w zależności od stężenia tego leku. Na podstawie uzyska-
nych krzywych stężenie – efekt obliczono średnią wartość EC50 dla karbacholu, która wyniosła 
2,44×10–6 [M/l].
  Wnioski:  Uzyskane wyniki potwierdziły, że atropina skutecznie hamuje skurcze wywołane karbacholem, 
spełnia więc warunki stawiane antagonistom kompetycyjnym. Atropina powodowała przesunię-
cie krzywych dla karbacholu w prawo. Pirenzepina, selektywnie blokująca receptory muskary-
nowe typu M1 dała podobne rezultaty. Dowiedziono, że w preparacie mięśniówki gładkiej dna 
żołądka, receptory typu M1 występują nie tylko presynaptycznie, lecz także postsynaptycznie.
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Carbachol, in the range of concentrations between 10–8 and 
10–3, causes ileal smooth muscle contraction that depends 
on concentration. Concentration-effect curves for carba-
chol were used for determination of the average value of 
EC50, which amounts to 2.44(±0.11)×10–7 for n=9. Results 
are presented on Fig. 1 and in Table 1.
A series of experiments made with dibenamine, an irre-
versible antagonist, was used for determination of Ka, a 
dissociation constant, which amounts to 1.26(±0.09)×10–5 
for n=9. This constant was used for determination of a cu-
rve, presenting dependence between%RA/RT and concen-
tration of carbachol (Fig. 1).
Pirenzepine, a relatively selective receptor antagonist of M1 
type, in the range of concentrations between 10–7 and 10–6 
[M/l], causes concentration-dependent shift of concentra-
tion-effect curve for carbachol to the right, maintaining ma-
ximum reaction. Based on these curves, EC50 values were 
determined in the presence of increasing concentrations 
of pirenzepine. Results are shown in Table 1. The average 
for n=9 is shown by concentration-effect curve for carba-
chol in the presence of pirenzepine in concentrations be-
tween 10–7 and 10–6, presented on Fig. 2.
The use of pirenzepine, a competitive receptor agonist M1, 
causes shift of concentration-effect curve (for carbachol) 
to the right, maintaining maximum reaction.
According to analysis of curves, we can deduce that pirenze-
pine meets the conditions posed to competitive antagonists, 
whereas the average value of IC50 determined for pirenze-
pine amounts to 1.89×10–9 [M/l]. Fig. 3 presents concen-
tration-effect curve for antagonistic activity of pirenzepine 
in relation to a non-selective muscarinic receptor agonist 
and carbachol.
Atropine, as a non-selective muscarinic receptor antago-
nist, causes concentration-dependent shift of concentra-
tion-effect curve (for carbachol) to the right, maintaining 
maximum reaction. According to the determined curve, 
we can deduce that atropine meets the conditions posed 
to competitive antagonists.
dIscussIon
According to testing conducted to date, we can confirm that 
rat’s ileum contains muscarinic receptors. Existence of the-
se receptors acknowledges antagonistic activity of atropine, 
a non-selective muscarinic receptor antagonist [13,14,15]. 
According to presented data, pirenzepine, a relatively se-
lective receptor antagonist shows activity similar to atro-
pine. According to analysis of curves and EC50 values for 
carbachol determined during experiments, we can deduce 
that pirenzepine meets the conditions of competitive an-
tagonism in relation to carbachol, a non-selective musca-
rinic receptor agonist. The IC50 value for pirenzepine, de-
termined during experiments, amounts to 1.89(±0.16)×10–8 
[M/l]. During testing conducted in the laboratory on an in-
sulated gastric fundus with darifenacin, it was determined 
that M3 type receptor occurs in smooth muscle and inter-
mediates in contraction release. IC50 value for darifena-
cin amounts to 3.89(±0.12)×10–8 [M/l]. In addition, accor-
ding to testing conducted to date, it was determined that 
Fig. 1.  Concentration-effect curve for carbachol and RA/RT dependence 
curve for carbachol. Constant KA 1.26(±0.09)×10–5. Points marked 
on the curve present average values and SE for n=9
Fig. 2.   Influence of increasing concentrations (from 10–7 to 10–6 [M/l]) 
of pirenzepine on concentration-effect curve for carbachol. Points 
marked on the curve present average values and SE ± for n =9
Drug n EC50 [M/l] KA [M/l]
Carbachol 9 2.44×10–7 1.26×10–5
Carbachol + Pirenzepine 10–7 9 6.22×10–7 1.37×10–5
Carbachol+ Pirenzepine 3×10–7 9 1.44×10–6 1.46×10–5
Carbachol+ Pirenzepine 10–6 9 4.71×10–6 1.51×10–5
Table 1. Influence of carbachol on the reaction of ileal smooth muscle contraction before and after the use of increasing concentrations of pirenzepine
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parasympathetic nervous system and fulfill a function mo-
dulating secretion of acetylcholine [3,10,16]. Activation of 
these receptors causes release of acetylcholine from ends 
of the parasympathetic nervous system. During testing, it 
was determined that M1 type receptor occurs in smooth 
muscle and intermediates in contraction release [8,11,12].
conclusIons
•	 	 Carbachol	in	concentrations	between	10–7 and 10–6 [M/l] 
causes concentration-dependent isometric ileal smooth 
muscle contraction.
•	 	 Atropine,	a	non-selective	muscarinic	receptor	antago-
nist, meets the conditions of competitive antagonists.
•	 	 Pirenzepine,	a	relatively	selective	muscarinic	receptor	
antagonist of M1 type, breaks contraction induced by 
carbachol and meets the conditions posed to competiti-
ve antagonists.
•	 	 The	results	suggest	occurrence	of	M1 type receptors in 
rat’s ileum.
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Fig.3.   Presentation of concentration-effect curve determined for 
antagonistic activity of pirenzepine on ileal smooth muscle. 
The average value of IC50 pirenzepine for n=9 amounts to 
1.89(±0.16)×10–8 [M/l]
Fig. 4.   Presentation of concentration-effect curve determined for 
antagonistic activity of atropine on ileal smooth muscle. The average 
value of IC50 atropine for n=9 amounts to 1.76(±0.08)×10–8 [M/l]
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